NASDAQ:SMMT Summit Therapeutics (SMMT) Stock Price, News & Analysis $13.30 -0.04 (-0.30%) (As of 09:47 AM ET) Add Compare Share Share Today's Range$13.05▼$13.4950-Day Range$6.89▼$13.3452-Week Range$1.52▼$13.49Volume209,433 shsAverage Volume2.92 million shsMarket Capitalization$9.64 billionP/E RatioN/ADividend YieldN/APrice Target$14.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Summit Therapeutics alerts: Email Address Summit Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside7.4% Upside$14.33 Price TargetShort InterestBearish20.72% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.19Based on 17 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.27) to ($0.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.28 out of 5 starsMedical Sector906th out of 924 stocksPharmaceutical Preparations Industry421st out of 426 stocks 1.5 Analyst's Opinion Consensus RatingSummit Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageSummit Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Summit Therapeutics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted20.72% of the float of Summit Therapeutics has been sold short.Short Interest Ratio / Days to CoverSummit Therapeutics has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Summit Therapeutics has recently decreased by 4.51%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldSummit Therapeutics does not currently pay a dividend.Dividend GrowthSummit Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SMMT. Previous Next 2.3 News and Social Media Coverage News SentimentSummit Therapeutics has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Summit Therapeutics this week, compared to 2 articles on an average week.Search Interest25 people have searched for SMMT on MarketBeat in the last 30 days. This is an increase of 47% compared to the previous 30 days.MarketBeat FollowsOnly 9 people have added Summit Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Summit Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders88.30% of the stock of Summit Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.61% of the stock of Summit Therapeutics is held by institutions.Read more about Summit Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Summit Therapeutics are expected to decrease in the coming year, from ($0.27) to ($0.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Summit Therapeutics is -83.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Summit Therapeutics is -83.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSummit Therapeutics has a P/B Ratio of 121.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Summit Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Preserve GoldTrump is sounding the alarmEurope is one of the latest to release a central bank digital currency and along with it, new cash rules. Christine Lagarde, President of the European Central Bank, shared "Now we have in Europe this threshold, above 1,000 euros you cannot pay cash… if you get caught you are fined or you are going to jail". Are you prepared?Click here to get your complimentary retirement guide! About Summit Therapeutics Stock (NASDAQ:SMMT)Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.Read More SMMT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SMMT Stock News HeadlinesAugust 21 at 9:46 PM | lse.co.ukSummit Therapeutics Share Price (SMMT.US)August 21 at 8:52 AM | americanbankingnews.comSummit Therapeutics' (SMMT) "Buy" Rating Reiterated at HC WainwrightAugust 22, 2024 | Behind the Markets (Ad)Secure this "AI Fuel" Stock Before the Billionaires Buy It AllAccording to the Washington Post, America is running out of a crucial component for AI. Without this "AI fuel," firms like NVIDIA would have to shut down their operations.August 18, 2024 | ca.finance.yahoo.comSMMT Sep 2024 8.000 putAugust 18, 2024 | ca.finance.yahoo.comSMMT Sep 2024 3.000 callAugust 18, 2024 | finance.yahoo.comSMMT Sep 2024 13.000 put (SMMT240920P00013000)August 17, 2024 | ca.finance.yahoo.comSMMT Sep 2024 12.000 callAugust 17, 2024 | americanbankingnews.comQ3 2024 EPS Estimates for Summit Therapeutics Inc. Lowered by HC Wainwright (NASDAQ:SMMT)August 22, 2024 | Behind the Markets (Ad)Secure this "AI Fuel" Stock Before the Billionaires Buy It AllAccording to the Washington Post, America is running out of a crucial component for AI. Without this "AI fuel," firms like NVIDIA would have to shut down their operations.August 15, 2024 | americanbankingnews.comHC Wainwright Weighs in on Summit Therapeutics Inc.'s Q3 2024 Earnings (NASDAQ:SMMT)August 14, 2024 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Shares Gap Up to $10.78August 13, 2024 | americanbankingnews.comSummit Therapeutics (NASDAQ:SMMT) Coverage Initiated by Analysts at HC WainwrightAugust 12, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Summit Therapeutics (SMMT) with Buy RecommendationAugust 12, 2024 | finance.yahoo.comHARMONi-2, Featuring Ivonescimab Monotherapy vs. Pembrolizumab Monotherapy, to be Showcased in Presidential Symposium at WCLC 2024August 11, 2024 | prnewswire.comTwo Ivonescimab (PD-1/VEGF) Results including Phase 3 Monotherapy versus Pembrolizumab Monotherapy in First-Line Treatment for PD-L1 Positive NSCLC to Be Presented at WCLC 2024August 8, 2024 | 247wallst.com3 Small-Cap Stocks That Could Outperform the “Magnificent 7”August 6, 2024 | investorplace.comSMMT Stock Earnings: Summit Therapeutics Beats EPS for Q2 2024August 3, 2024 | seekingalpha.comSummit Therapeutics May Have Further Upside From HereSee More Headlines Receive SMMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today8/22/2024Next Earnings (Estimated)11/05/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SMMT CUSIPN/A CIK1599298 Webwww.summitplc.com Phone650-460-8308Fax44-12-3544-3999Employees110Year FoundedN/APrice Target and Rating Average Stock Price Target$14.33 High Stock Price Target$16.00 Low Stock Price Target$13.00 Potential Upside/Downside+7.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-614,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-121.21% Return on Assets-53.69% Debt Debt-to-Equity RatioN/A Current Ratio2.35 Quick Ratio2.35 Sales & Book Value Annual Sales$700,000.00 Price / Sales13,807.66 Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book121.27Miscellaneous Outstanding Shares724,540,000Free Float82,132,000Market Cap$9.67 billion OptionableOptionable Beta-0.97 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Robert W. Duggan (Age 79)Co-CEO & Executive Chairman Dr. Mahkam Zanganeh D.D.S. (Age 54)M.B.A., Co-CEO, President & Director Comp: $657.81kMr. Ankur Dhingra (Age 47)Chief Financial Officer Comp: $530kMr. Manmeet Singh Soni (Age 46)COO & Director Comp: $591.5kProf. Dame Kay Davies DBE (Age 73)FRS CBE, Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor Ms. Abby Guzman MurphyHead of Human ResourcesMs. Divya Chari (Age 56)Head of Global Clinical Operations Mr. Dave GancarzChief Business & Strategy Officer?Mr. Will BlackHead of Information Technology?Dr. Betty Y. Chang Ph.D.Head of Research, Oncology & Inflammation?More ExecutivesKey CompetitorsModernaNASDAQ:MRNABioNTechNASDAQ:BNTXTeva Pharmaceutical IndustriesNYSE:TEVABeiGeneNASDAQ:BGNEGenmab A/SNASDAQ:GMABView All CompetitorsInsiders & InstitutionsSusquehanna International Group LLPBought 114,800 shares on 8/16/2024Ownership: 0.000%Millennium Management LLCBought 1,942,858 shares on 8/15/2024Ownership: 0.277%The Manufacturers Life Insurance Company Bought 128,934 shares on 8/15/2024Ownership: 0.029%Susquehanna Fundamental Investments LLCBought 18,501 shares on 8/15/2024Ownership: 0.010%AQR Capital Management LLCBought 62,114 shares on 8/15/2024Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions SMMT Stock Analysis - Frequently Asked Questions How have SMMT shares performed this year? Summit Therapeutics' stock was trading at $2.61 on January 1st, 2024. Since then, SMMT shares have increased by 411.1% and is now trading at $13.34. View the best growth stocks for 2024 here. How were Summit Therapeutics' earnings last quarter? Summit Therapeutics Inc. (NASDAQ:SMMT) announced its earnings results on Monday, November, 15th. The company reported ($0.20) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.09. The company earned $6.12 million during the quarter. When did Summit Therapeutics IPO? Summit Therapeutics (SMMT) raised $40 million in an IPO on Thursday, March 5th 2015. The company issued 3,500,000 shares at a price of $11.54 per share. JMP Securities and Oppenheimer & Co. acted as the underwriters for the IPO and Needham was co-manager. Who are Summit Therapeutics' major shareholders? Top institutional investors of Summit Therapeutics include Millennium Management LLC (0.28%), Federated Hermes Inc. (0.08%), Bank of New York Mellon Corp (0.04%) and TD Asset Management Inc (0.04%). Insiders that own company stock include Robert W Duggan, Ankur Dhingra and Mahkam Zanganeh. View institutional ownership trends. How do I buy shares of Summit Therapeutics? Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Summit Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Summit Therapeutics investors own include Energy Transfer (ET), Summit Therapeutics (SUMM), Sarepta Therapeutics (SRPT), Gilead Sciences (GILD), CBL & Associates Properties (CBL) and SandRidge Permian Trust (PER). This page (NASDAQ:SMMT) was last updated on 8/22/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAir Force quietly working with sub $10 stock on new techThere is a little-known energy technology stock that has made an incredible breakthrough… Which could becom...DTI | SponsoredUS developing “superweapon” to defeat China and Russia?Our new superweapon is a gift to every patriot. I predict the devastating new tech behind this weapon will cre...Paradigm Press | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredAmazon coin set to soar 25X – starting August 19thChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | Sponsored625,000% GainThe recent crypto pullback has been brutal, causing widespread panic among investors. But for us, it’s just an...Crypto Swap Profits | SponsoredThe #1 A.I. Crypto You Don’t Own (YET!)Markets are volatile right now—stocks, cryptos, you name it. But here's a crucial fact everyone is missing:...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
